1. Home
  2. ICFI vs IMCR Comparison

ICFI vs IMCR Comparison

Compare ICFI & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ICF International Inc.

ICFI

ICF International Inc.

HOLD

Current Price

$68.89

Market Cap

1.8B

ML Signal

HOLD

Logo Immunocore Holdings plc

IMCR

Immunocore Holdings plc

HOLD

Current Price

$29.73

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ICFI
IMCR
Founded
1969
2008
Country
United States
United Kingdom
Employees
N/A
N/A
Industry
Professional Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.8B
1.7B
IPO Year
2006
2016

Fundamental Metrics

Financial Performance
Metric
ICFI
IMCR
Price
$68.89
$29.73
Analyst Decision
Buy
Buy
Analyst Count
4
10
Target Price
$99.25
$66.33
AVG Volume (30 Days)
398.9K
366.2K
Earning Date
05-07-2026
05-07-2026
Dividend Yield
0.82%
N/A
EPS Growth
N/A
30.39
EPS
1.12
0.25
Revenue
$1,229,162,000.00
$249,428,000.00
Revenue This Year
$4.12
$14.57
Revenue Next Year
$5.33
$8.21
P/E Ratio
$15.02
$122.22
Revenue Growth
3.72
43.05
52 Week Low
$64.34
$27.47
52 Week High
$101.71
$40.71

Technical Indicators

Market Signals
Indicator
ICFI
IMCR
Relative Strength Index (RSI) 46.73 47.99
Support Level $64.43 $28.23
Resistance Level $74.37 $34.35
Average True Range (ATR) 3.18 1.35
MACD 0.45 0.16
Stochastic Oscillator 43.73 53.87

Price Performance

Historical Comparison
ICFI
IMCR

About ICFI ICF International Inc.

ICF International Inc provides professional services and technology-based solutions to government and commercial clients, including management, marketing, technology, and policy consulting and implementation services. Its services support clients that operate in four key markets that include Energy, Environment, Infrastructure and Disaster Recovery; Health and Social Programs and Security and Other Civilian & Commercial. The Company's majority clients are United States federal government departments and agencies. It operates in a single segment, which is providing professional services.

About IMCR Immunocore Holdings plc

Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.

Share on Social Networks: